5FAH

KALLIKREIN-7 IN COMPLEX WITH COMPOUND1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.1 Å
  • R-Value Free: 0.197 
  • R-Value Work: 0.188 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Small-molecule factor D inhibitors targeting the alternative complement pathway.

Maibaum, J.Liao, S.M.Vulpetti, A.Ostermann, N.Randl, S.Rudisser, S.Lorthiois, E.Erbel, P.Kinzel, B.Kolb, F.A.Barbieri, S.Wagner, J.Durand, C.Fettis, K.Dussauge, S.Hughes, N.Delgado, O.Hommel, U.Gould, T.Mac Sweeney, A.Gerhartz, B.Cumin, F.Flohr, S.Schubart, A.Jaffee, B.Harrison, R.Risitano, A.M.Eder, J.Anderson, K.

(2016) Nat.Chem.Biol. 12: 1105-1110

  • DOI: 10.1038/nchembio.2208
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination. Complement component 3 (C3) is the central component of the system. Activation of C3 can be initiated by three distinct routes-the class ...

    Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination. Complement component 3 (C3) is the central component of the system. Activation of C3 can be initiated by three distinct routes-the classical, the lectin and the alternative pathways-with the alternative pathway also acting as an amplification loop for the other two pathways. The protease factor D (FD) is essential for this amplification process, which, when dysregulated, predisposes individuals to diverse disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH). Here we describe the identification of potent and selective small-molecule inhibitors of FD. These inhibitors efficiently block alternative pathway (AP) activation and prevent both C3 deposition onto, and lysis of, PNH erythrocytes. Their oral administration inhibited lipopolysaccharide-induced AP activation in FD-humanized mice. These data demonstrate the feasibility of inhibiting the AP with small-molecule antagonists and support the development of FD inhibitors for the treatment of complement-mediated diseases.


    Organizational Affiliation

    Novartis Institutes for BioMedical Research, Novartis Pharma AG, Novartis Campus, Basel, Switzerland.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Kallikrein-7
A
224Homo sapiensMutation(s): 1 
Gene Names: KLK7 (PRSS6, SCCE)
EC: 3.4.21.117
Find proteins for P49862 (Homo sapiens)
Go to Gene View: KLK7
Go to UniProtKB:  P49862
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ACT
Query on ACT

Download SDF File 
Download CCD File 
A
ACETATE ION
C2 H3 O2
QTBSBXVTEAMEQO-UHFFFAOYSA-M
 Ligand Interaction
5VT
Query on 5VT

Download SDF File 
Download CCD File 
A
(2~{S})-~{N}2-[2-(4-methoxyphenyl)ethyl]-~{N}1-(naphthalen-1-ylmethyl)pyrrolidine-1,2-dicarboxamide
C26 H29 N3 O3
HMNBKWNEJGMBRQ-DEOSSOPVSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
5VTIC50: 700 nM (100) BINDINGDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.1 Å
  • R-Value Free: 0.197 
  • R-Value Work: 0.188 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 42.611α = 90.00
b = 60.343β = 90.00
c = 80.633γ = 90.00
Software Package:
Software NamePurpose
BUSTERrefinement
DENZOdata reduction
MOLREPphasing
SCALEPACKdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-10-26
    Type: Initial release
  • Version 1.1: 2016-11-02
    Type: Database references
  • Version 1.2: 2016-11-23
    Type: Database references